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2211-3355/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 26 January 2016 Objective. The objective of this study was to determine if a difference exists in the proportion of visits for the
prescribing of angiotensin converting enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARBs) in dia-
betic patients during 2007–2010.
Methods. This retrospective, cross-sectional, observational study included adults diagnosed with diabetes
mellitus from the National Ambulatory Medical Care Survey (NAMCS) during 2007–2010. Weighted chi-
square tests and a multivariable logistic regression model were used to analyze associations between ACEI/
ARB prescriptions and predictors of interest. Odds ratios and 95% conﬁdence intervals were reported.
Results. An unweighted total of 13,590 outpatient ambulatory care visits were identiﬁed for adult patients
with diabetes without contraindications to ACEIs or ARBs in the NAMCS for the years studied. No statistically sig-
niﬁcant increase in the proportion of visits with an ACEI/ARB prescription was identiﬁed for years 2007–2010
(28.1% in 2007 to 32.2% in 2010). Females (OR 0.78, 95% CI 0.69- 0.89), patients 18–39 years old (OR 0.56, 95%
CI 0.43- 0.75), and Medicare users (OR 0.81, 95% CI 0.70- 0.94) were signiﬁcantly less likely to receive an ACEI/
ARB prescription. Patients with hypertension (OR 2.80, 95% CI 2.39-3.29), hyperlipidemia (OR 1.42, 95% CI
1.22-1.65), and ischemic heart disease (OR 1.36, 95% CI 1.10-1.70) were signiﬁcantly more likely to receive an
ACEI/ARB prescription.
Conclusions. Despite extensive evidence showing the beneﬁts of ACEI/ARB medications in diabetic patients,
disparities of treatment remain evident.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Diabetes is a chronic disease that increasingly affects a growing
percentage of the American population. Currently, it is the seventh
leading cause of death in the United States, with 9.3% of the US popula-
tion having a diagnosis (Centers for Disease Control and Prevention,
2014). Diabetes care is complex and requires an expansive range of
interventions for improved disease outcomes. Concurrent disease states
such as hypertension, hyperlipidemia, and ischemic heart disease (IHD)
add to this complexity. The Standards of Medical Care in Diabetes,
compiled annually by the American Diabetes Association (ADA),
recommend that the ﬁrst line treatment for patients with diabetes ande inhibitor; ARB, angiotensin
l Care Survey; ADA, American
rval; NCHS, National Center for
S.L. Ibrahim),
bell.edu (M.A. Holland),
. This is an open access article underhypertension should be an angiotensin-converting enzyme inhibitor
(ACEI) or an angiotensin receptor blocker (ARB) (American Diabetes
Association, 2010). ACE inhibitors are also recommended in patients
with diabetes and known cardiovascular disease to reduce the risk of
cardiovascular-related events and mortality (American Diabetes
Association, 2010). Data from several clinical trials support these
recommendations and provide insight for the treatment of diabetes
complications in various subsets of the diabetic population (Eurich
et al., 2004; Yusuf et al., 2000; Lindholm et al., 2002). More speciﬁcally,
thesemedications have shownbeneﬁt beyond blood pressure optimiza-
tion and have nephroprotective and cardioprotective properties
(Fioretto and Solini, 2005; Parving et al., 2001; Viberti et al., 2002).
Despite these recommendations and guidelines, previous research
indicates that a large proportion of diabetes patients are not receiving
these medications as indicated (Rosen, 2006). The Rosen study used
data from the National Health and Nutrition Examination Survey and
found national estimates of ACEI/ARB use in the elderly diabetic
population to be no higher than 53%, despite risk factors indicating
that the majority of all of these patients should be prescribed an ACEI/
ARB. Additional data regarding national trends for ACEI/ARBthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographics/Patient Characteristics of Diabetic Patients in the NAMCS, 2007-2010a.
Variable Number of Patient Visits (%)
Race
Other 15,380,788 (4.7)
Black 49,212,081 (14.9)
White 265,913,006 (80.5)
Sex
Female 240,904,506 (53.5)
Male 209,517,989 (46.5)
Ethnicity
Hispanic/Latino 41,692,227 (12.8)
Not Hispanic/Latino 284,077,272 (87.2)
Age Group
18–39 31,603,090 (7.0)
40–54 97,941,690 (21.7)
55 + 320,877,715 (71.2)
Payment Type
Otherb 23,173,473 (5.3)
Medicaid 36,537,103 (8.3)
Medicare 201,495,671 (45.9)
Private 178,194,033 (40.6)
Region
Midwest 99,830,986 (22.2)
Northeast 79,311,364 (17.6)
West 85,928,435 (19.1)
South 185,351,710 (41.2)
Hypertension
Yes 288,771,724 (64.1)
No 161,650,771 (35.9)
Ischemic Heart Disease
Yes 48,481,513 (10.8)
No 401,940,982 (89.2)
Hyperlipidemia
Yes 185,793,309 (41.2)
No 264,629,186 (58.8)
Chronic Renal Failure
Yes 25,925,596 (5.8)
No 424,496,899 (94.2)
a Weighted data. Reference groups are listed last for each variable.
b Other insurance type includes worker's compensation, self- payment, and no charge.
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study was to determine if there was an association between the
proportion of visits with a prescription for ACEI/ARB medications and
the year of visit in adult diabetic patients who participated in the Na-
tional Ambulatory Medical Care Survey (NAMCS) between the years
2007–2010. Additionally, several demographic and comorbidity vari-
ables were analyzed to determine their effect on receipt of medication.
Methods
Data Source
This study was a retrospective, cross-sectional, observational
analysis of data collected in the NAMCS. The NAMCS is an annual,
national probability sample of visits made to the ofﬁces of non-
federally employed physicians classiﬁed by the American Medical
Association or the American Osteopathic Association as “ofﬁce-based,
patient care”. Physicians in the specialties of anesthesiology, pathology
and radiology are excluded. Further details on the types of contact
excluded can be found at (http://www.cdc.gov/nchs/ahcd/ahcd_scope.
htm#namcs_scope). The survey has been conducted annually from
1973 to 1981, in 1985, and annually from 1989 to present. The multi-
staged sample design is composed of 3 stages that involves probability
samples of primary sampling units (PSUs), physician practices within
PSUs, and patient visits within practices. Details of the sampling
procedure can be found at (http://www.cdc.gov/nchs/ahcd/ahcd_
scope.htm#namcs_scope).
The data collected included information on patient demographics,
reasons for visit, vital signs, continuity of care, diagnosis for the visit,
diagnostic screening services, health education, non-medication
treatment, medications and immunizations, provider type, visit disposi-
tion, and time spent with provider. On average, for the years 2007–
2010, approximately 68% of physicians sampled met the criteria
required for database eligibility. The eligibility criteria include ofﬁce
based physicians who are principally engaged in patient care activities
that are non-federally employed and are not in specialties of anesthesi-
ology, pathology, or radiology. Of the eligible (in-scope) physicians, the
average unweighted response ratewas approximately 60% (McCaig and
Burt, 2012).
NAMCS datasets from 2007 to 2010 were included in this study.
Patients that were 18 years of age or older with an International
Classiﬁcation of Diseases, Ninth Revision (ICD-9) code for diagnosis of
diabetes (249.00–250.93) in any of the diagnoses ﬁelds (DIAG1-
DIAG3) or a ‘Yes’ response to the DIABETES variable were included in
the ﬁnal analysis dataset. Pregnant patients (ICD-9 code v22.2) or
those diagnosed with angioedema (ICD-9 code 995.1) were excluded.
Across the four years included in this study, a total of 13,590 rawpatient
visit records met the inclusion/exclusion criteria.
The survey datawere analyzed using the sampled visit weight that is
the product of the corresponding sampling fractions at each stage in the
sample design. The sampling weights have been adjusted by NCHS for
survey nonresponse as appropriate within each database, yielding an
unbiased national estimate of visit occurrences, percentages, and
characteristics (McCaig and Burt, 2012).
Because of the complex sample design, sampling errors were
determined using the SAS SURVEYFREQ and SURVEYLOGISTIC proce-
dures which take into account the clustered nature of the sample
(Centers for Disease Control and Prevention, 2014).The appropriate
SAS procedure options (NOMCAR and DOMAIN) to address missing
data and to utilize domains to determine accurate variance estimates
were implemented in the analyses as recommended by the NCHS.
This data was previously collected, de-identiﬁed and cleaned by the
CDC and is available to the public at ftp://ftp.cdc.gov/pub/Health_
Statistics/NCHS/Datasets/NAMCS/. The study was submitted to the
Campbell University Institutional Review Board (IRB) and received an
exemption.Outcome Variable
The outcome variable of interest was ACEI/ARB prescription (Yes
versus No), where the denominator was the number of cases meeting
the inclusion/exclusion criteria. ACEI/ARB prescription was deﬁned by
a code of ‘042’ or ‘056’ for any of the level 2 Multum database drug
category variables (http://www.multum.com 2013).
Independent Variables
The choice of independent variables was made based on factors
determined to be relevant to ACEI/ARB prescription in diabetics but
was limited by the data available in the NAMCS surveys. The selected
variables and information on their coding is located in Table 1. Note
that tobacco use was excluded from all analyses due the high
percentage (N30%) of missing data.
Statistical analysis
A series of weighted odds ratios (ORs) and corresponding 95%
conﬁdence intervals (CIs) were analyzed and reported to determine
whether there was any association between ACEI/ARB prescription
(Yes vs. No) and each of the independent variables shown in Table 1
in adult patients with diabetes. The term ‘weighted’ refers to the NCHS
determined survey design weights that allow extrapolation of the raw
data to national estimates.
A multivariable logistic regression model was also constructed for
ACEI/ARB prescription in order to evaluate the predictive value of each
independent variable, adjusting for covariates of interest. As a primary
Table 3
Individual Chi-Square Results for Predictors of ACEI/ARB Prescriptions for Diabetic Patients
in the NAMCS, 2007-2010a.
Variable ACEI/ARB Prescription
n (%)b
Overall p-value OR
(95% CI)
Race 0.7694
Other 5,040,051 (32.8) 1.13 (0.82, 1.55)
Black 14,916,110 (30.3) 1.01 (0.83, 1.22)
White 80,318,053 (30.2) Referent
Sex b0.0001
Female 65,414,653 (27.2) 0.76 (0.69, 0.84)
Male 68,982,725 (32.9) Referent
Ethnicity 0.1052
Hispanic/Latino 11,323,979 (27.2) 0.84 (0.68, 1.04)
Not Hispanic/Latino 87,418,363 (30.8) Referent
Age Group b0.0001
18–39 4,669,615 (14.8) 0.37 (0.29, 0.48)
40–54 27,591,438 (28.2) 0.84 (0.73, 0.97)
55+ 102,136,325 (31.8) Referent
Payment Type 0.0231
Otherc
Medicaid/SCHIP
5,791,478 (25.0)
9,251,717 (25.3)
0.76 (0.60, 0.96)
0.78 (0.62, 0.97)
Medicare 61,378,898 (30.5) 1.00 (0.89, 1.13)
Private 54,217,361 (30.4) Referent
Region 0.0752
Midwest 30,980,923 (31.0) 1.20 (0.98, 1.46)
Northeast 25,817,965 (32.6) 1.29 (1.02, 1.62)
West 27,050,280 (31.5) 1.23 (1.01, 1.49)
South 50,548,210 (27.3) Referent
Hypertension b0.0001
Yes 109,397,454 (37.9) 3.33 (2.93, 3.80)
No 24,999,924 (15.5) Referent
Hyperlipidemia b0.0001
Yes 69,459,880 (37.4) 1.84 (1.63, 2.07)
No 64,937,498 (24.5) Referent
Ischemic Heart Disease b0.0001
Yes 19,414,863 (40.0) 1.67 (1.38, 2.01)
No 114,982,515 (28.6) Referent
Chronic Renal Failure 0.1863
Yes 8,701,625 (33.6) 1.20 (0.91, 1.58)
No 125,695,753 (29.6) Referent
a Analyses appropriately weighted and clustered to reﬂect national estimates.
b Percent in each stratum of variable.
c Other insurance type includes worker's compensation, self- payment, and no charge.
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were included in themultivariablemodel.Weighted, adjusted ORswith
corresponding 95% CIs for each level of each variable included in the
model (in comparison to each variable's reference group) were report-
ed. The term ‘adjusted’ refers to the effect of the covariates in themodel
on the other variables. All analyseswere conductedwith SAS version 9.3
(Copyright © 2012 SAS Institute Inc.) Per NCHS recommendations, any
variable i) missing more than 30% of its data ii) with a survey estimate
based on less than 30 records or iii) with a relative standard error
(RSE) ofmore than 30%was excluded from the analyses due to potential
unreliability. As this was a retrospective, hypothesis generating study,
no adjustments for multiple comparisons were made.
Results
An unweighted total of 13,590 visits were identiﬁed for adult
patients with diabetes without contraindications to ACEIs or ARBs in
the NAMCS between the years of 2007 and 2010 (Table 1). Accounting
for the weighting, the majority of patients were white (80.5%), female
(53.5%), 55 or older (71.2%) and not Hispanic/Latino (87.2%).
Approximately 64.1% of the study population had hypertension, 41.2%
had hyperlipidemia, 10.8% had IHD and 5.8% had chronic renal failure
(CRF).
While the proportion of visits with ACEI/ARB prescriptions in adult
diabetic patients who participated in the NAMCS in 2007–2010 was
increasing (28.1% in 2007 to 32.2% in 2010), all of the conﬁdence
intervals for the odds ratios of each year compared to 2007 contained
unity, suggesting no signiﬁcant difference in the proportion across
survey years (Table 2).
Based on individualweighted ORs and their associated CIs, several of
the predictor variables of interest were found to be signiﬁcantly associ-
ated with the proportion of visits with an ACEI/ARB prescription
(Table 3). Females (OR 0.76, 95% CI 0.69-0.84), patients 40–54 (vs
55+) (OR 0.84, 95% CI 0.73-0.97), patients 18–39 (vs 55+) (OR 0.37,
95% CI 0.29-0.48), Medicaid/SCHIP users (vs private payers) (OR 0.78,
95% CI 0.62-0.97) and those with “Other” form of payment (vs private
payers) (OR 0.76, 95% CI 0.60-0.96) were all signiﬁcantly less likely to
be prescribed an ACEI/ARB. Conversely, patients visiting physician of-
ﬁces in the Northeast (OR 1.29, 95% CI 1.02-1.62) and the West (OR
1.23, 95% CI 1.01-1.49) were signiﬁcantly more likely to be prescribed
an ACEI/ARB than those in the South. In addition, hypertensive patients
(OR 3.33, 95% CI 2.93-3.80), hyperlipidemic patients (OR 1.84, 95% CI
1.63-2.07) and patients with IHD (OR 1.67, 95% CI 1.38-2.01) were
signiﬁcantly more likely than those without each respective condition
to be prescribed an ACEI/ARB.
According to the multivariable logistic regression analysis which
adjusted for the covariates included in the model (Table 4), patients
were signiﬁcantly less likely to be prescribed an ACEI/ARB relative to
the referent group if they were female (adjusted OR 0.78, 95% CI 0.69-
0.88), aged 18–39 (adjusted OR 0.56, 95% CI 0.43-0.75) or on Medicare
(adjustedOR0.81, 95% CI 0.70-0.94). Conversely, based on themultivar-
iable logistic regressionmodel, patientswere signiﬁcantlymore likely to
be prescribed an ACEI/ARB relative to the referent group if they had
hypertension (adjusted OR 2.81, 95% CI 2.40-3.29), hyperlipidemiaTable 2
Individual Chi- Square Results of ACEI/ARB Prescriptions by Year for Diabetic Patients in
the NAMCS, 2007-2010a.
Variable ACEI/ARB Prescription n (%)b Overall p-value OR (95% CI)
0.1789
2010 35,958,841 (32.2) 1.22 (0.99, 1.50)
2009 40,049,037 (30.4) 1.12 (0.91, 1.38)
2008 30,007,234 (28.3) 1.01 (0.83, 1.24)
2007 28,382,266 (28.1) Referent
a Analyses appropriately weighted and clustered to reﬂect national estimates.
b Percent in each stratum of variable.(adjusted OR 1.42, 95% CI 1.22-1.64) or IHD (adjusted OR 1.36, 95% CI
1.10-1.70). Second order interaction terms were investigated, found to
contribute nothing signiﬁcant to the understanding of the overall
results and were excluded from the ﬁnal reported model.
Discussion
While no statistically signiﬁcant difference was found in the
prescribing rates of ACEI and ARBs in adult diabetic patients included
in the NAMCS during the years 2007 to 2010, the prescribing rate did
consistently increase from 28.1% in 2007 to 32.2% in 2010. However,
across all four years, only 29.6% of the study population received a pre-
scription. These results indicate that though adherence to the ADA
guidelines as they pertain to ACEI/ARB prescribing appears to be im-
proving, the guidelines are not being implemented as indicated for the
diabetic population. These results, based on the most recently available
data, are suggestive of a lower prescription rate of these medications as
compared with previous studies which found 43% of the older diabetic
population received appropriate therapy when indicated (Rosen,
2006). In addition the Rosen study found that only 53% of patients in
the highest risk categories received ACEI/ARB therapy. These percent-
ages are higher than those found in the present study, which found
only an average of 29.6% of the study population to receive an ACEI/
ARB prescription.
Cardiovascular disease risk factors, such as hypertension, are known
to be widespread in diabetic patients (Goldberg, 2003). However, de-
spite 64.1% of patients having hypertension, only 37.9% of these patients
Table 4
Multivariable Logistic Regression Model of ACEI/ARB Prescription for Diabetic Patients
in the NAMCS, 2007-2010a.
Variable Adjusted OR (95% Wald CI)
Year
2010 1.17 (0.94, 1.47)
2009 1.12 (0.87, 1.43)
2008 0.98 (0.77, 1.26)
2007 Referent
Age
40–54 0.87 (0.72, 1.05)
18–39 0.56 (0.43, 0.75)
55 + Referent
Payment Type
Otherb 0.80 (0.62, 1.03)
Medicaid/SCHIP 0.91 (0.71, 1.17)
Medicare 0.81 (0.70, 0.94)
Private Referent
Sex
Female 0.78 (0.69, 0.89)
Male Referent
Region
West 1.23 (0.94, 1.60)
Midwest 1.10 (0.88, 1.37)
Northeast 1.19 (0.85, 1.67)
South Referent
Hypertension
Yes 2.80 (2.39, 3.29)
No Referent
Hyperlipidemia
Yes 1.42 (1.22, 1.65)
No Referent
Ischemic Heart Disease
Yes 1.36 (1.10, 1.70)
No Referent
Chronic Renal Failure
Yes 1.06 (0.77, 1.45)
No Referent
a Analyses appropriately weighted and clustered to reﬂect national estimates.
b Other insurance type includes worker's compensation, self- payment, and no charge.
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line therapy. This is alarming due to the fact that hypertension contrib-
utes to cardiovascular disease, which causes approximately 70% of
deaths associated with diabetes. Thus, prevention in this subset of the
diabetic population is critical in decreasing mortality (Basina and
Kraemer, 2002). Conversely, 10.8% of patients had IHD yet 40.0%
received anACEI/ARBprescription. These results suggest that physicians
are more likely to follow the ADA recommendations in patients with
known cardiovascular disease but are not taking the appropriate
preventive measures in the high risk population.
There is an enormous economic burden associated with the
extensive complications from diabetes. Although hyperlipidemia is not
directly correlated with ACEI/ARB usage, it is correlated with the risk
of developing cardiovascular disease; therefore it is also interesting to
note that patients with hyperlipidemia were signiﬁcantly more likely
to receive a prescription. Effective preventive measures should be
taken and proper medication management should be implemented to
aid in the reduction of this ﬁscal burden (Seaquist, 2014).
Not surprisingly, age also appears to have an important association
with ACEI/ARB prescribing, as the 2007 ADA guidelines recommended
that patients over the age of 55 with a cardiovascular risk factor such
as hypertension, smoking, dyslipidemia or history of cardiovascular
disease be given an ACEI/ARB in order to reduce the risk of a cardiovas-
cular event (American Diabetes Association, 2007). In 2008 and 2009,
this age cutoff was reduced to 40 (American Diabetes Association,
2008; American Diabetes Association, 2009). In our study, patients 55
or older received a higher percentage of ACEI/ARB prescriptions than
either of the other age groupings, which is in line with the established
recommendations. Payment type and gender were also determined tohave an association with ACEI/ARB prescriptions. The signiﬁcant
payment type associations suggest that disparities between prescribing
rates of these medications still exist and parallels previous research
highlighting differences in diabetic treatment based on payment type
(Devoe et al., 2009). The differences in prescribing patterns between
genders in this study highlight another disparity. Previous research
indicates that female diabetic patients experience higher rates of all-
cause mortality, with CVD mortality remaining higher in this subset
than either gender without diabetes (Arnetz et al., 2014). Conversely,
our study determined that femaleswere less likely thanmales to receive
medications that prevent these problems. Due to the gender differences
identiﬁed in this study, as well as notable gender differences in the
progression of CVD, future research that includes separate analyses
based on gender may be warranted to determine if similar trends are
identiﬁed in each gender separately.
Similar to Rosen et al. which looked at national prevalence trends
using the Kaiser Permanente Northern California Diabetes Registry, no
differences in prescriptions were found in race and ethnicity. Rosen
et al. did identify disparities in black diabetic patients with albuminuria
receiving signiﬁcantly less ACEI/ARB prescriptions; however the current
study did not examine this subset of individuals for comparison (Rosen
et al., 2004).
Research performed in other health care settings have shown that
ACEI/ARBusage can be as high as 74% in patients that have both diabetes
and hypertension, demonstrating that compliance to guidelines can be
achieved (Rosen et al., 2004). This study's ﬁndings indicate that there
is still room for improvement in diabetes care and management when
analyzing a national subset of ambulatory care patients in the US.
Previous research suggests that guidelines and treatment algorithms
be simpliﬁed to allow additional patients to receive effective diabetes
treatment (Rosen, 2006). Additionally, Toth et al. suggests that
treatment goals that are presented in guidelines may need to become
more realistic and applicable in clinical practice (Toth et al., 2003).
Diabetic patients often have multiple disease states that require the
use of numerous medications in order to obtain control, which results
in polypharmacy. Incorporating patient commitment and compliance
into the development of treatment regimens is also important in the
prevention of diabetic complications (Winocour, 2002). Using the
most effective regimens that include the propermedications can ensure
patients achieve optimal targets and outcomes.
Strengths and Limitations
Due to the nature of the NAMCS survey, it was not possible to assess
compliance with the medication, only receipt of the prescription. Also,
the survey limits the number of medications that can be reported
which may not adequately capture every drug that a patient is
prescribed. Despite these limitations, the study utilized data from the
NAMCS, which is a nationally renowned database that weights and
clusters data, allowing for ﬁndings to be extrapolated to the national
population. Further, this study was also the ﬁrst, to our knowledge, to
examine the effectiveness of recent national guidelines as well as to
assess disparities in receipt of these pharmacological treatments based
on the most current publicly available data.
Conclusion
Although an increase in ACEI/ARB prescribing rates over the years
was identiﬁed, there is still progress to be made in the utilization of
these drug classes in diabetic patients in order to comply with current
ADA guidelines. Despite an apparent increase in the proportion of pre-
scriptions in recent years, there are still large percentages of diabetic pa-
tients with known indications who are not receiving appropriate
treatment. This study highlights the need for additional research into
the low ACEI/ARB prescription rates in the diabetic population, with
particular emphasis on females and the younger aged population.
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